Treatment of chronic hepatitis C infection with cryoglobulinemia

Current Opinion in Rheumatology

Volumn 14, Issue 3, 2002, Pages 231-237

  Della Rossa, Alessandra ^a   Tavoni, Antonio ^a   Baldini, Chiara ^a   Bombardieri, Stefano ^a  

^a Rheumatology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CYTOTOXIC AGENT; MACROGOL DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN; STEROID;

APHERESIS; ARTHRALGIA; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DOSE RESPONSE; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PALLIATIVE THERAPY; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PURPURA; REVIEW; SJOEGREN SYNDROME; VASCULITIS;

ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERONS; RIBAVIRIN;

EID: 0036226099     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200205000-00006     Document Type: Review

References (46)

1. Pathology of hepatitis C virus infection
2. Long term study of hepatitis C virus replication in non-A, non-B hepatitis
3. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
4. Mixed cryoglobulinemia: A cross road between autoimmune and lymphoproliferative disorders
5. Mixed cryoglobulinemia: Clinical aspects and long term follow up of 40 patients
6. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis
7. Cryoglobulinemic neuropathy related to hepatitis C virus infection: Clinical, laboratory and neurophysiologic study
8. Cryoglobulinemia
9. Lung involvement in essential mixed cryoglobulinemia
10. Mixed cryoglobulinemia: New concepts
11. Hepatitis C virus and mixed cryoglobulinemia
12. From essential mixed cryoglobulinemia to virus induced autoimmunity: Ten years of research in mixed cryoglobulinemia
13. Immune complex behavior during prolonged plasma exchange in essential mixed cryoglobulinemia and systemic lupus erythematosus
14. Guidelines for the management of essential mixed cryoglobulinemia
15. Treatment of autoimmune and extrahepatic manifestations of HCV infection
16. Low antigen content diet in the treatment of patients with mixed cryoglobulinemia
17. Treatment of renal involvement of mixed cryoglobulinemia with prolonged plasma exchange
18. Plasma exchange in mixed cryoglobulinemia. Effects on renal, liver and neurologic involvement
19. Double filtration plasma-apheresis in the treatment of cryoglobulinemic glomerulonephritis
20. Plasma exchange in essential mixed cryoglobulinemia
21. Association between hepatitis C virus and non Hodgkin lymphoma, and effects of viral infection on histologic subtype and clinical course
22. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy
23. Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment
24. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon
25. Long-term results of therapy with interferon alpha for type II essential mixed cryoglobulinemia
26. Mixed cryoglobulinemia responsive to interferon-alpha
27. Interferon-alpha in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial
28. Predictors of long term response to high dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection
29. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
30. Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia
31. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia
32. Mixed cryoglobulinemia associated with hepatitis C virus infection: A predictor factor for treatment with interferon?
33. Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis
34. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection
35. Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity
36. Ribavirin in hepatitis C related cryoglobulinemia
37. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinemia
38. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha
39. Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia
40. Hepatitis C virus infection
41. Recent advances in prevention and treatment of hepatitis C virus infections
42. Interferon alpha with or without ribavirin for chronic hepatitis C: Systematic review of randomised trials
43. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C
44. Peg-interferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
45. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon beta
46. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen